Technical Analysis for NNVC - NanoViricides, Inc.

Grade Last Price % Change Price Change
grade A 10.08 9.92% 0.91
NNVC closed up 12.54 percent on Thursday, February 27, 2020, on 1.3 times normal volume.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up
Historical NNVC trend table...

Date Alert Name Type % Chg
20 DMA Support Bullish -2.33%
MACD Bullish Signal Line Cross Bullish -2.33%
Pocket Pivot Bullish Swing Setup -2.33%
Wide Range Bar Range Expansion -2.33%
Multiple of Ten Bullish Other -2.33%
Outside Day Range Expansion -2.33%
Wide Bands Range Expansion -2.33%
Crossed Above 20 DMA Bullish 9.92%
Pocket Pivot Bullish Swing Setup 9.92%
Wide Bands Range Expansion 9.92%

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

NanoViricides, Inc. a nano-biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of viral infections. The company is developing anti-influenza drug candidates at advanced pre-clinical stage, which include two FluCide drugs comprising NV-INF-2, an oral anti-influenza drug and NV-INF-1, a injectable anti-influenza drug for novel strain of H7N9, Bird Flu H5N1, and other Highly Pathogenic Influenzas; HIVCide, an anti-human immunodeficiency virus (HIV) drug candidate that could enable a functional cure for HIV/AIDS; HerpeCide, a skin cream or gel formulation for the treatment of oral and genital herpes lesions; Nanoviricide anti-viral eye drops against external eye viral infections; and DengueCide, a treatment against Dengue viruses. It is also developing RabiCide, an anti-rabies nanoviricide; and Nanoviricide for the treatment of various strains of Ebola and Marburg filoviruses. The company has licenses to develop drugs for the treatment of human viral diseases, such as H5N1 (avian flu), human influenza, human immunodeficiency virus (HIV/AIDS), hepatitis B virus, hepatitis C virus, herpes simplex virus, and rabies; and dengue viruses, Japanese encephalitis virus, West Nile virus, viruses causing viral conjunctivitis and ocular herpes, and Ebola/Marburg viruses, as well as viral diseases of the eye comprising epidemic kerato-conjunctivitis and herpes keratitis. NanoViricides, Inc. was founded in 2005 and is based in West Haven, Connecticut.
Medicine Medical Specialties Infectious Diseases Infection Influenza HIV HIV/Aids Antiviral Drug Virus Herpes Simplex Virus Rabies Viral Diseases Ebola Herpes Simplex Epidemiology Genital Herpes Human Influenza Viral Disease

Is NNVC a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 19.2
52 Week Low 1.27
Average Volume 4,564,935
200-Day Moving Average 4.28
50-Day Moving Average 5.82
20-Day Moving Average 8.68
10-Day Moving Average 7.76
Average True Range 2.40
ADX 40.0
+DI 45.07
-DI 16.89
Chandelier Exit (Long, 3 ATRs ) 11.99
Chandelier Exit (Short, 3 ATRs ) 12.72
Upper Bollinger Band 13.42
Lower Bollinger Band 3.94
Percent B (%b) 0.67
BandWidth 109.21
MACD Line 0.62
MACD Signal Line 0.61
MACD Histogram 0.0136
Fundamentals Value
Market Cap 653.27 Million
Num Shares 63.3 Million
EPS -0.17
Price-to-Earnings (P/E) Ratio -60.71
Price-to-Sales 0.00
Price-to-Book 3.04
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 17.88
Resistance 3 (R3) 17.90 15.40 16.62
Resistance 2 (R2) 15.40 13.47 15.39 16.20
Resistance 1 (R1) 12.86 12.29 11.61 12.84 15.78
Pivot Point 10.36 10.36 9.74 10.35 10.36
Support 1 (S1) 7.82 8.43 6.57 7.80 4.86
Support 2 (S2) 5.32 7.25 5.31 4.44
Support 3 (S3) 2.78 5.32 4.02
Support 4 (S4) 2.76